Mymetics to manufacture HER-Vaxx cancer immunotherapy

By Zachary Brennan contact

- Last updated on GMT

Related tags: Immune system, Clinical trial

Mymetics to manufacture HER-Vaxx cancer immunotherapy
Swiss-based Mymetics has agreed with Australian biotech Imugene to manufacture and develop its cancer immunotherapy HER-Vaxx, which is expected to enter into a Phase I/II clinical trial in 2015.

Mymetics will use its experience in virosome-based vaccines and integrating antigens in viral membranes to manufacture the Imugene HER-Vaxx cancer immunotherapy vaccine candidate.

HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Ronald Kempers, CEO of Mymetics said the deal “further confirms and recognizes Mymetics as a global leader and niche player in the development and formulation of virosomes and integration of membrane proteins and peptides for immunotherapy and vaccine candidates​.”

Dr Nick Ede, Executive Director Imugene added, "Mymetics uses the same vaccine delivery platform for infectious diseases that we are using for our immuno-oncology program and together both companies will work to exploit the potential value of influenza-based virosomes​.”

On top of the manufacturing deal, Mymetics currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal influenza, malaria, herpes simplex virus and the RSV vaccine. The HIV-1 vaccine has completed a Phase I trial in healthy human volunteers. A Phase Ib clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase.

Related topics: Bio Developments

Related news

Follow us

Products

View more

Webinars